Literature DB >> 23288907

Developmental analysis and influence of genetic background on the Lhx3 W227ter mouse model of combined pituitary hormone deficiency disease.

Kelly L Prince1, Stephanie C Colvin, Soyoung Park, Xianyin Lai, Frank A Witzmann, Simon J Rhodes.   

Abstract

Combined pituitary hormone deficiency (CPHD) diseases result in severe outcomes for patients including short stature, developmental delays, and reproductive deficiencies. Little is known about their etiology, especially the developmental profiles and the influences of genetic background on disease progression. Animal models for CPHD provide valuable tools to investigate disease mechanisms and inform diagnostic and treatment protocols. Here we examined hormone production during pituitary development and the influence of genetic background on phenotypic severity in the Lhx3(W227ter/W227ter) mouse model. Lhx3(W227ter/W227ter) embryos have deficiencies of ACTH, α-glycoprotein subunit, GH, PRL, TSHβ, and LHβ during prenatal development. Furthermore, mutant mice have significant reduction in the critical pituitary transcriptional activator-1 (PIT1). Through breeding, the Lhx3(W227ter/W227ter) genotype was placed onto the 129/Sv and C57BL/6 backgrounds. Intriguingly, the genetic background significantly affected viability: whereas Lhx3(W227ter/W227ter) animals were found in the expected frequencies in C57BL/6, homozygous animals were not viable in the 129/Sv genetic environment. The hormone marker and PIT1 reductions observed in Lhx3(W227ter/W227ter) mice on a mixed background were also seen in the separate strains but in some cases were more severe in 129/Sv. To further characterize the molecular changes in diseased mice, we conducted a quantitative proteomic analysis of pituitary proteins. This showed significantly lower levels of PRL, pro-opiomelanocortin (ACTH), and α-glycoprotein subunit proteins in Lhx3(W227ter/W227ter) mice. Together, these data show that hormone deficiency disease is apparent in early prenatal stages in this CPHD model system. Furthermore, as is noted in human disease, genetic background significantly impacts the phenotypic outcome of these monogenic endocrine diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23288907      PMCID: PMC3548188          DOI: 10.1210/en.2012-1790

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  57 in total

1.  The homeodomain coordinates nuclear entry of the Lhx3 neuroendocrine transcription factor and association with the nuclear matrix.

Authors:  G E Parker; R M Sandoval; H A Feister; J P Bidwell; S J Rhodes
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

2.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

3.  A recessive mutation resulting in a disabling amino acid substitution (T194R) in the LHX3 homeodomain causes combined pituitary hormone deficiency.

Authors:  Susanne Bechtold-Dalla Pozza; Stefan Hiedl; Julia Roeb; Peter Lohse; Raleigh E Malik; Soyoung Park; Mario Durán-Prado; Simon J Rhodes
Journal:  Horm Res Paediatr       Date:  2012-01-26       Impact factor: 2.852

4.  Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency.

Authors:  Amrit P S Bhangoo; Chad S Hunter; Jesse J Savage; Henry Anhalt; Steven Pavlakis; Emily C Walvoord; Svetlana Ten; Simon J Rhodes
Journal:  J Clin Endocrinol Metab       Date:  2006-01-04       Impact factor: 5.958

5.  A novel alignment method and multiple filters for exclusion of unqualified peptides to enhance label-free quantification using peptide intensity in LC-MS/MS.

Authors:  Xianyin Lai; Lianshui Wang; Haixu Tang; Frank A Witzmann
Journal:  J Proteome Res       Date:  2011-09-21       Impact factor: 4.466

Review 6.  The role of homeodomain transcription factors in heritable pituitary disease.

Authors:  Kelly L Prince; Emily C Walvoord; Simon J Rhodes
Journal:  Nat Rev Endocrinol       Date:  2011-07-26       Impact factor: 43.330

7.  Regulation of thyrotropin biosynthesis. Discordant effect of thyroid hormone on alpha and beta subunit mRNA levels.

Authors:  J A Gurr; I A Kourides
Journal:  J Biol Chem       Date:  1983-09-10       Impact factor: 5.157

8.  Analysis of mouse models carrying the I26T and R160C substitutions in the transcriptional repressor HESX1 as models for septo-optic dysplasia and hypopituitarism.

Authors:  Ezat Sajedi; Carles Gaston-Massuet; Massimo Signore; Cynthia L Andoniadou; Daniel Kelberman; Sandra Castro; Heather C Etchevers; Dianne Gerrelli; Mehul T Dattani; Juan Pedro Martinez-Barbera
Journal:  Dis Model Mech       Date:  2008-11-06       Impact factor: 5.758

9.  Mutations in the LHX3 gene cause dysregulation of pituitary and neural target genes that reflect patient phenotypes.

Authors:  Jesse J Savage; Chad S Hunter; Surilda L Clark-Sturm; Tanya M Jacob; Roland W Pfaeffle; Simon J Rhodes
Journal:  Gene       Date:  2007-06-07       Impact factor: 3.688

10.  Lhx4 and Prop1 are required for cell survival and expansion of the pituitary primordia.

Authors:  Lori T Raetzman; Robert Ward; Sally A Camper
Journal:  Development       Date:  2002-09       Impact factor: 6.868

View more
  5 in total

1.  Cell-specific actions of a human LHX3 gene enhancer during pituitary and spinal cord development.

Authors:  Soyoung Park; Rachel D Mullen; Simon J Rhodes
Journal:  Mol Endocrinol       Date:  2013-10-07

2.  Multi-omic profiling of pituitary thyrotropic cells and progenitors.

Authors:  Alexandre Z Daly; Lindsey A Dudley; Michael T Peel; Stephen A Liebhaber; Stephen C J Parker; Sally A Camper
Journal:  BMC Biol       Date:  2021-04-15       Impact factor: 7.431

3.  Issues and applications in label-free quantitative mass spectrometry.

Authors:  Xianyin Lai; Lianshui Wang; Frank A Witzmann
Journal:  Int J Proteomics       Date:  2013-01-16

4.  LHX3 interacts with inhibitor of histone acetyltransferase complex subunits LANP and TAF-1β to modulate pituitary gene regulation.

Authors:  Chad S Hunter; Raleigh E Malik; Frank A Witzmann; Simon J Rhodes
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

5.  Bioinformatic Analysis of Differential Protein Expression in Calu-3 Cells Exposed to Carbon Nanotubes.

Authors:  Pin Li; Xianyin Lai; Frank A Witzmann; Bonnie L Blazer-Yost
Journal:  Proteomes       Date:  2013-10-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.